Home' The Source : Third Quarter 2012 Contents IDEAL FO HE ILIAC
Prior to use, see the complete 'Directions for Use' for more information on Indications, Contraindications, Warnings, Precautions, Adverse Events, and Operator's Instructions. CAUTION: Federal Law (USA) restricts this device to sale by or on the order of a physician. INDICATIONS
FOR USE: Epic Vascular Self-Expanding Stent System is indicated for the improvement of luminal diameter in patients with de novo or restenotic symptomatic atherosclerotic lesions up to 120 mm in length in the common and/or external iliac arteries, with a reference vessel
diameter between 5 mm and 11 mm. CONTRAINDICATIONS: There are no known contraindications. WARNINGS: Stenting across a bifurcation or side branch could compromise future diagnostic or therapeutic procedures; Persons allergic to nickel-titanium may suffer an allergic
response to this implant; Improper stent size selection may lead to stent migration or stent jumping; As with any type of intravascular implant, infection secondary to contamination of the stent may lead to thrombosis, pseudoaneurysm, or rupture into a neighboring organ or into
the retroperitoneum; The stent may cause thrombus or distal emboli to migrate from the site of the implant down the arterial lumen; The long-term outcome following repeat dilatation of endothelialized stents is unknown at present; In patients with poor kidney function, contrast
agents may precipitate kidney failure. PRECAUTIONS: Safety and effectiveness has not been demonstrated in patients with the following characteristics: Highly calcified lesions resistant to PTA; Persistent, intraluminal thrombus at the target lesion; Uncorrected bleeding disorders
or patients who cannot receive anticoagulation or anti-platelet aggregation therapy; Perforated vessels evidenced by extravasation of contrast media; Lesions that are within or adjacent to an aneurysm; Vessels with excessive tortuosity. The delivery system is not designed for use
with power injection systems. Always use an introducer or guide sheath for the implant procedure, to protect the access site. Only advance the stent delivery system over a guidewire. Never dilate the stent using a balloon that is larger in diameter than the labeled diameter of the
stent. The stent delivery system is not intended for arterial blood monitoring. In the event of thrombosis of the expanded stent, thrombolysis and/or PTA should be considered. In the event of complications such as infection, pseudoaneurysms or fistula formation, surgical removal
of the stent may be required. ADVERSE EVENTS: Potential adverse events that may occur following intravascular stent implantation include, but are not limited to: Abscess; Allergic reaction (to drug, contrast, device or other); Amputation; Aneurysm; Angina/coronary ischemia;
Arrhythmia; Arteriovenous fistula; Death; Drug reactions; Embolization (air, plaque, thrombus, device, or other); Entanglement of delivery system in deployed stent; Fever; GI bleeding; Hemorrhage/hematoma; Hypotension/hypertension; Myocardial Infarction (MI); Need for urgent
intervention or surgery; Pseudoaneurysm; Renal insufficiency or failure; Restenosis of stented artery; Sepsis/infection; Stent fracture; Stent migration; Stent misplacement/jumping; Stent thrombosis with possible neurological injury; Stroke; Thrombosis/thrombus; Tissue ischemia/
necrosis; Vasospasm; Vessel injury, examples include perforation, dissection, intimal tear, rupture; Vessel occlusion.
Epic is a registered trademark of Boston Scientific Corporation or its affiliates. Illustrations are property of Boston Scientific Corporation. Illustrations are not necessarily to scale. 2012 Boston Scientific Corporation or its affiliates. All rights reserved. PI-68207-AA JUN2012
Defining tomorrow, today.
Epic provides exactly the right balance.
FLEXIBILI Y ADIAL FO CE
F AC U E
Contact your local sales representative to learn more
or visit www.bostonscientific.com/epic
Visit us at booth #124 at the HealthTrust University Conference & Vendor Fair.
Links Archive Fourth Quarter 2012 Second Quarter 2012 Navigation Previous Page Next Page